hcv

Uprifosbuvir (MK-3682) is a uridine nucleoside monophosphate prodrug inhibitor of hepatitis C virus NS5B RNA polymerase with antiviral activity for the study of chronic hepatitis C virus.

Resiquimod (R848) is a Toll-like receptor 7 8 (TLR7 TLR8) agonist that induces cytokine upregulation. Resiquimod is an immunomodulator with antitumor and antiviral activity.

Ribavirin (Tribavirin) is a synthetic nucleoside analog of ribofuranose with activity against hepatitis C virus and other RNA viruses.

Ombitasvir (ABT-267) is an orally bioavailable and potent inhibitor of the hepatitis C virus (HCV) non-structural protein 5A (NS5A).with EC50s of 0.82 to 19.3 pM against HCV genotypes 1 to 5, and 366 pM against genotype 6a

Glecaprevir (ABT-493) is an HCV NS3 4A protease inhibitor, (IC50s: 3.5-11.3 nM).

Syrosingopine is a dual inhibitor of MCT1 and MCT4, 60 times more potent against MCT4, preventing lactate and H+ efflux. Syrosingopine is an orally available antihypertensive drug with potential for cancer research in combination with metformin.

Platycodin D3 is a NF-κB inhibitor, it could as expectorants in diverse inflammatory pulmonary diseases, it can regulate the production and secretion of airway mucin; it can significantly enhance mitogen- and OVA-induced splenocyte proliferation in the OVA-immunized mice. Platycodin D3 also exerts anti-Hepatitis C virus (HCV) activity.

PSI-6130 (R 1656) is a potent and selective HCV NS5B polymerase inhibitor. PSI-6130 inhibits HCV replication with a mean IC50 of 0.6 μM.

GSK-A1 is a specific inhibitor of PI4KA, also inhibited calcium-driven PRL secretion without affecting calcium signaling and Prl expression. GSK-A1 has anti-hepatitis C virus (HCV) potential.

HCV-IN-29 is an inhibitor of the hepatitis C virus (HCV).

HCV-IN-30 is an HCV NS5A replication complex inhibitor (IC50s: 901 and 102 nM for genotypes 1a and 1b replicons).

Sofosbuvir (GS 7977) is a uridine monophosphate analog inhibitor of hepatitis C virus (HCV) polymerase NS5B that is used as an antiviral agent in the treatment of chronic hepatitis C.

AG-1478 (NSC-693255) (Tyrphostin AG-1478) is a selective EGFR inhibitor.

HCV-IN-7 is an orally active and potent pan-genotypic HCV NS5A inhibitor (IC50s: 3-47 pM) with a superior pan-genotypic profile, good pharmacokinetic properties, and favorable liver uptake.

HCV-IN-3 is a hepatitis C virus (HCV) NS3 4a protein inhibitor with an IC50 of 20 μM and a Kd of 29 μM.

HCV-IN-44 (compound 28) is an inhibitor of the HCV NS5B protein, effective in suppressing HCV virus replication and useful for researching HCV infection [1].

HCV Core Protein (59-68) is a peptide containing residues 59-68 from the core protein of the Hepatitis C virus (HCV) [1].

HCV-IN-39 (Compound 18a) is a potent, orally active nucleoside inhibitor of hepatitis C virus (HCV), effective against the GT1a replicon (EC50: 0.259 μM), GT1b replicon (EC50: 0.434 μM), and GT1b CES1 replicon (EC50: 0.069 μM).

HCV-IN-33 [Compound (S)-3i] is an inhibitor of HCV entry.

HCV-IN-34 is an orally active HCV entry inhibitor. HCV-IN-35 exhibits good antiviral efficacy (EC50: 0.010 μM, CC50 (half of the maximum cytotoxic concentration): 7.50 μM).

HCV-IN-35 is a potent inhibitor of HCV and shows potential for infectious disease research.

HCV-086, a RNA-directed RNA polymerase (NS5B) inhibitor, is used for the treatment of HCV infection.

HCV NS4A Protein (18-40) (JT strain) is a peptide derived from residues 18 to 40 of the HCV NS4A protein, enhancing the catalytic efficiency of NS3 protease [1].

HCV Peptide (131-140) is a research-grade peptide used in studying the hepatitis C virus (HCV) [1].